AstraZeneca Vietnam announces oncology distribution partner in Việt Nam

Tuesday, Aug 22, 2023 11:28

The agreement signing ceremony between AstraZeneca Vietnam and Hoàng Đức Pharmaceutical and Medical Supplies Company. — Photo courtesy of AstraZeneca Vietnam

Global science-led biopharmaceutical company AstraZeneca Vietnam has recently announced Hoàng Đức Pharmaceutical and Medical Supplies Company as its oncology distribution partner in Việt Nam.

Besides advancing patient access to innovative medicines, the partnership between the two companies will increase the capacity of domestic pharmaceutical distributors, enhance the sustainability of the pharmaceutical supply chain, which will strengthen the comprehensive development of Việt Nam's pharmaceutical industry.

Moreover, the collaboration aims at contributing to the implementation of the National Strategy for Pharmaceutical Industry Development and the UK-Việt Nam Free Trade Agreement (UKVFTA).

"Reducing the burden of suffering from cancer has always been one of the top priorities of the health sector, in which screening, early detection and highly effective treatment with advanced therapies are of great significance," said Lê Ngọc Danh, head of pharmacy unit, HCM City’s Department of Health.

“AstraZeneca is proud to accompany Việt Nam’s healthcare development for nearly three decades. The agreement is our continued commitment to improving access to medicine for patients, accelerating innovation to transform cancer treatment, as well as building enduring value for Vietnamese patients and society,” said Nitin Kapoor, chairman and general director of AstraZeneca Vietnam.

Over the last three decades in Việt Nam, with nearly 600 employees nationwide, AstraZeneca has implemented several impactful programmes in collaboration with the Ministry of Health and healthcare partners to promote awareness, prevention, and early detection.

Among them are the Healthy Lung Programme to improve the quality of outpatient management for asthma, chronic obstructive pulmonary disease, and lung cancer; the Young Health Programme to prevent and reduce non-communicable diseases (NCD) risk behaviours among young people; and the CaReMe programme to transform the cardiovascular - kidney - metabolic care ecosystem. — VNS

Comments (0)